Company: IPHYF
Filing Date: 2025-04-30
Form Type: 20-F
Source: 0001598599-25-000042
Chunk: 206

Company: Innate Pharma SA
Filing Date: 2025-04-30
Form: 20-F
Item: Item 6
Chunk 206
---
ate in December 2001. Between 2001 and 2007, he was in R& D positions, initially as a scientist in the immunology team, before becoming team manager, and finally becoming responsible for research programs. He is in charge of business development for the company since 2007, adding product portfolio strategy since 2017 and research and early development since 2024. Yannis Morel holds a Ph. D. in oncology (from Aix-Marseille University) and is an alumnus of Ecole Normale Supérieure de Paris Saclay (previously Cachan), with a BS in physical and molecular chemistry.

Sonia Quaratino, M. D., Ph. D., joined Innate Pharma in November 2023 as Executive Vice President and Chief Medical Officer (CMO) and as a member of Innate's Leadership Team. Sonia Quaratino has over 25 years of experience in basic research, clinical development and translational medicine. Before joining Innate, Sonia Quaratino was CMO at Georgiamune INC (USA), and prior to that, CMO at Kymab (UK), a clinical-stage biopharmaceutical company focused on immune-mediated diseases and immuno-oncology, until its acquisition by Sanofi in 2021. Previously, Sonia Quaratino was Global Program Lead in Oncology at Novartis (Switzerland) and Senior Medical Director Oncology and Advisor in Immunology at Merck Serono (Germany). She was Professor of Immunology at the University of Southampton in the UK and her research has been published in high-impact scientific journals.

Supervisory Board

Irina Staatz-Granzer, Ph. D., Chairwoman of the Supervisory Board since January 1, 2024 and member of the Supervisory Board since June 23, 2009. Irina Staatz-Granzer has held business development positions at Hermal (subsidiary of Merck KGaA), Boots Healthcare International, Knoll (BASF Pharma, later Abbott) and as Chief Executive Officer of Scil Technology Gmbh, Chief Executive Officer of U3 Pharma AG and Chief Executive Officer of Blink Biomedical SAS. Irina Staatz-Granzer also serves as Chairman of PLCD (German Pharma Licensing Club). She founded and is currently Chief Executive Officer of Staatz Business Development & Strategy. She is also member of the Supervisory Board of Aelis Farma SAS. Irina Staatz